SecBot SecBot

ANL

Adlai Nortye Group Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001944552 Biotech & Drug Discovery
$10.84 +0.26 (+2.46%)
Oct 27 4:00 PM ET · prev $10.58
Market cap
$681.3M
Small cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$27.00
+149% · range $20.00–49.00
1 year
+617.9%
from $1.51 · Oct 27
30 days
−29.6%
from $15.40
52-week range
$0.8800–16.60
−35% from high · low Dec 8
Avg volume 20D
336.9K
Oct 8 spike 985.3K
Short interest
🔒 Subscribers only
Insider net
−$411.2K
0 buyers · 3 sellers · 12 mo
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
12
analyzed by SecBot
SecBot read BULLISH 10 reports · 90 days
Balance 0 bearish · 5 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 8/10
Strongest BULLISH Adlai Nortye announced clinical trial collaboration and supply agreements with Lilly and Merck KGaA…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    3 insiders sold $411.2K.

  • InstitutionsMIXED

    Q2 2026: 5 added (1 new), 3 trimmed or exited. Largest new: Point72 Asset Management, $24.6M.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    23% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$24.6M
in new stakes
FundMoveSharesValue
BALYASNY ASSET MANAGEMENT L.P.DOUBLED3,061,668$35.2M
Point72 Asset Management, L.P.NEW2,140,664$24.6M
Woodline Partners LPDOUBLED455,733$5.2M
RENAISSANCE TECHNOLOGIES LLCADD94,100$1.1M
AMERIPRISE FINANCIAL INCTRIM86,700$997.0K
UBS Group AGTRIM52,895$608.3K
Tidal Investments LLCTRIM44,354$510.1K
GEODE CAPITAL MANAGEMENT, LLCADD14,174$163.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy4Buy6Hold1Sell0Strong Sell0
12-month targets · 6 analysts

Price is below the lowest target. Median implies +149%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 10, 2026Jefferies
INITIATE
INITIATEBuy
Sep 8, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 22, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
May 28, 2026Oppenheimer
INITIATE
INITIATEOutperform
May 14, 2026Jones Trading
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$411.2K
sold · 3 insiders
DateInsiderTypeValue
Sep 30, 2026
Ji Ping
Director
SELL$80.2K
Sep 30, 2026
Ji Ping
Director
SELL$79.8K
Sep 29, 2026
Ji Ping
Director
SELL$3.4K
Sep 22, 2026
Ji Ping
Director
SELL$83.2K
Aug 26, 2026
Ye Xiaofeng
CFO
SELL$80.8K
Aug 24, 2026
Ye Xiaofeng
CFO
SELL$83.9K
Jun 10, 2026
Ji Ping
Director
OTHER136,667 sh
May 13, 2026
LU YANG
CEO
SELL$131.80

Earnings setup

Estimates
$0.03
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q$0.03$0.03–$0.03+0.0%$0.00
Next Q-$0.30-$0.30–-$0.30+0.0%$3.5M
Current FY-$0.18-$0.32–-$0.06+0.0%$17.2M
Next FY-$0.29-$0.70–-$0.08+0.0%$7.6M

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 SEC
Adlai Nortye announced clinical trial collaboration and supply agreements with Lilly and Merck KGaA, Darmstadt…
6-K — Impact 5/10
Oct 15, 2026 Press
Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA for cetuximab…
Impact 4/10
Oct 15, 2026 Contract
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monot
Sep 30, 2026 SEC
Adlai Nortye appointed Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings…
6-K — Impact 2/10
Sep 30, 2026 SEC
Adlai Nortye Group Ltd. filed a 6-K reporting that all resolutions presented at its September 30, 2026 Extraordinary…
6-K — Impact 2/10
Sep 30, 2026 Insider
Ji Ping sold 5,000 shares
Director @ $16.03 ($80.2K)
Sep 30, 2026 Insider
Ji Ping sold 5,000 shares
Director @ $15.95 ($79.8K)
Sep 29, 2026 Insider
Ji Ping sold 214 shares
Director @ $15.77 ($3.4K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 15, 2026
Contract
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the…
Sep 30, 2026
Press release
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a…
Aug 14, 2026
Earnings
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025
Aug 3, 2026
FDA
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
First-in-class pan-RAS(ON) ADC is cleared for clinical development
Jul 16, 2026
FDA
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
The first patient has been dosed in the intermittent weekly dosing (QW) arm of the ongoing Phase 1 clinical trial of AN9025, a pan-RAS(ON) inhibitor.

SecBot reports

12 filings · 2 press releases · 6 bullish · 0 bearish · 2 mixed · 4 neutral
All ANL filing & press-release reports (14)